Page 19 - Cipla

Cipla campaign hard-hitting; was aimed at opening people's eyes: Lav Dhruv

We launched the campaign with hoardings showing stark shots of the most polluted places in Delhi, along with a simple message, urging the audience to act quickly before it's too late

Cipla recalls 4,800 bottles of anti-HIV tablets from American market

As per the latest Enforcement Report by the USFDA, the reason for the recall of the bottles is 'failed dissolution specifications'

Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn

Acquisition to help the company build a specialty pipeline in the US

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

The approved products is a generic therapeutic equivalent version of Roche's Valcyte

Cipla shares continue to fall post Q2 results; plunge nearly 6%

At NSE, shares of the company dropped 5.87% to close at Rs 529.95

Cipla hits five-month low on weak outlook; down 12% in two days

The stock was down 5% at Rs 534, trading at its lowest level since June 6, 2018 on the BSE.

Cipla stock falls 7% on weak Q2 results; pressure on tender biz to continue

Company cautious on prospects, given supply disruptions & commodity inflation, among others

Cipla takes a cautious approach towards tender business to protect margins

Tender business, which accounts for around 20% of consolidated sales, came under pressure because of intense competition and aggressive pricing

Cipla records sharpest fall in one year post Q2 results; stock down 8%

The stock has dipped 8% to Rs 558 on the BSE after the pharmaceutical company posted 11% decline in its consolidated net profit at Rs 3.77 billion for Q2FY19.

Cipla gets final nod for generic version of Aralez's Toprol Xl ER tablets

Cipla's Metoprolol ER Tablets 50mg, 100mg, 200mg is AB-rated beta1-selective adrenoceptor blocking agent

Cipla plans expansion, aims to launch at least one product in US every year

In India, the company is by far the leader in the respiratory drugs segment, having a turnover of over Rs 18.93 billion

We are determined to make fearless living a habit: Cipla's Umang Vohra

'We are looking to provide end-to-end solutions in the area of disease management for Patients'

Cipla nears its 52-week high post Q1 results

The stock has rallied 4.6% to Rs 662 on the BSE in early morning trade, trading close to its 52-week high of Rs 663 touched on November 11, 2017.

Cipla plans acquisitions to enter new therapies, boost Africa business

The company is looking at inorganic growth opportunities to offset delays in product approvals

Cipla acquires 100% stake in South African pharmaceutical company Mirren

The transaction is subject to the approval by the Competition Commission of South Africa

Cipla gains 3% post USFDA approval for its generic HIV drug

The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.

Cipla surges 7% post March quarter results

The stock surged 7% to Rs 563, bouncing back 8% from its early morning low of Rs 520 on the BSE.

Cipla arm recalls multiple lots of antidepressant drug from US market

The report, however, did not mention the quantity of the product

Cipla stock: Healthy momentum in sales indicates strong earnings visibility

Cipla's relatively late entry into the US market is proving a blessing

Cipla rebounds after clarification on USFDA observations for Goa unit

The stock moved higher to Rs 558, bouncing back 7% from its early morning low of Rs 523 on the BSE.